AKT1 and cancer: Our findings that both BCL2L1 and MAPK1 are co‐expressed in key biological pathways related to drug resistance, apoptosis and PIK3‐AKT signaling are in agreement with other studies in both NSCLC and other cancer types [27, 37, 38, 39, 40].